Scarica l'app Stockscreener
2.97
0.67%
-0.02
Dopo l'orario di chiusura:
2.97
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail
Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada
Research Analysts Issue Forecasts for FULC FY2024 Earnings - MarketBeat
Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) - Yahoo Finance
Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 5c - StreetInsider.com
Fulcrum Therapeutics (NASDAQ:FULC) Receives Neutral Rating from HC Wainwright - MarketBeat
Expert Ratings For Fulcrum Therapeutics - Benzinga
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights - GuruFocus.com
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... - Yahoo Finance
Fulcrum Therapeutics appoints new independent director - Investing.com India
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 - The Manila Times
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fulcrum Therapeutics appoints new independent director By Investing.com - Investing.com UK
Fulcrum Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times
Fulcrum Therapeutics (FULC) to Present at Stifel Healthcare Conference | Investor Update | FULC Stock News - StockTitan
Fulcrum Therapeutics (FULC) Scheduled to Post Earnings on Wednesday - MarketBeat
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET - The Manila Times
Vanguard Group Inc's Strategic Acquisition in Fulcrum Therapeuti - GuruFocus.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock? - Yahoo Finance
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance
Ratios in Focus: Analyzing Fulcrum Therapeutics Inc (FULC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN
The FULC Stock Puzzle: Unraveling Fulcrum Therapeutics Inc’s Fluctuating Performance - The InvestChronicle
Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - SETE News
Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 12% this week, taking three-year losses to 88% - Simply Wall St
Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... - Yahoo Finance
Stock Traders Buy Large Volume of Call Options on Fulcrum Therapeutics (NASDAQ:FULC) - MarketBeat
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet? - Zacks Investment Research
Dimensional Fund Advisors LP Grows Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares - Yahoo Finance
Fulcrum Therapeutics Inc (FULC) stock on the rise: An overview - US Post News
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) - MSN
Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround - MSN
An analyst sees good growth prospects for Fulcrum Therapeutics Inc (FULC) - SETE News
Daily Market Movement: Fulcrum Therapeutics Inc (FULC) Sees a 0.84 Increase, Closing at 3.60 - The Dwinnex
Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Consensus PT from Analysts - MarketBeat
Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results - Investing.com
Are Fulcrum Therapeutics Inc (FULC) shares a good deal now? - US Post News
FULC Stock on the Rise: A Promising Investment - The InvestChronicle
Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results By Investing.com - Investing.com Australia
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 41.4% in September - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - AccessWire
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback - MSN
Fulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market Opportunity - MarketWatch
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):